A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patie...
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Denmark · Germany
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Suspended
- Enrollment listed in the registry
- 150
- Sponsor
- Central Institute of Mental Health
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark, Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-004335-23
- Official title
Show the full official title
A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patie...
Recruitment & locations
Denmark · Germany
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Central Institute of Mental Health, a research institute.
Is this study still recruiting?
The historical registry lists this study as suspended.
